Loading
Latest filing published 19 Oct 2026 for Elite Pharmaceuticals INC, €23k.
Based on 4 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Filings by Barry H. Dash span 2 companies, the busiest being Elite Pharmaceuticals Inc and GeoPharma, Inc. Between 3 July 2006 and 9 October 2026, the trades on record add up to 24 filings.
No open-market sale appears; the market trades are 7 purchases worth €55k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 14 share grants. Since January 2026: 2 purchases and no sales on the market.
A typical purchase (the median) is worth €7,435. Ninety days after publication, 4 purchases show a median change of -6.5%, with the price up in 25% of them. Past outcomes like these are no guarantee of what comes next.
Most recently, on 19 October 2026, the filings show an open-market purchase worth €23k in Elite Pharmaceuticals Inc. Filings reach the SEC (Form 4) feed a median of 5 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
19 of 19 declarations